(ANGO) AngioDynamics, Inc. Marketing Mix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(ANGO) AngioDynamics, Inc. Complete Analysis Pack
Visual. Strategic. Downloadable.
This AngioDynamics, Inc. 4P's Marketing Mix Analysis condenses the company’s Product, Price, Place, and Promotion strategy into a concise, actionable view and shows what the product is and how it’s used; this page already includes a real preview/sample of the analysis so you can evaluate content and style—purchase the full version to receive the complete ready-to-use report.
Product
2 ablation platforms: NanoKnife and Solero
AngioDynamics sells 2 ablation platforms, NanoKnife and Solero, for oncology and surgical care. NanoKnife is designed for precise soft-tissue ablation, while Solero uses microwave and radiofrequency energy for solid tumors, helping support minimally invasive workflows in specialty care. In fiscal 2025, AngioDynamics reported full-year net sales of about $300 million, with these systems part of its higher-value med-tech mix.
Vascular access: PICCs, midlines, ports, dialysis catheters
AngioDynamics, Inc. sells vascular access devices for short-term drug delivery and long-term infusion, including BioFlo, BioFlo Midline, BioFlo PICC, Xcela PICC, BioFlo Port, SmartPort, Vortex, and DuraMax. These lines support chemotherapy, antibiotics, and critical care, where secure access and lower complication risk matter. This category stays central to hospital and infusion-center demand, especially for oncology and dialysis care.
Endovascular therapies for thrombus, atherectomy, venous disease
AngioDynamics’ endovascular therapies target peripheral vascular disease and venous insufficiency, with tools for thrombus management and atherectomy. Peripheral artery disease affects about 8.5 million U.S. adults, and chronic venous disease is common in older patients, so demand is broad. This niche supports interventional vascular care with minimally invasive options used in hospitals and outpatient labs.
Oncology and surgical accessories: BioSentry, IsoLoc, Alatus
BioSentry, IsoLoc, and Alatus are 3 specialty accessories that widen AngioDynamics, Inc.'s oncology and surgical offer. They support procedures like tract sealing, endorectal imaging, and vaginal balloon packing, so they fit alongside core interventional and ablation tools.
- 3 accessory lines broaden clinical reach
- Targets oncology and surgical workflows
- Supports core interventional products
Angiographic catheters, guidewires, drainage kits
AngioDynamics supplies angiographic catheters, guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits to support diagnostic and interventional workflows across hospitals and specialty clinics. These tools sit in the company’s broad procedural portfolio, so they help reduce reliance on any single device line.
- Supports multiple specialty procedures
- Broadens exposure beyond one category
- Fits recurring hospital procurement cycles
That mix strengthens the Product side of AngioDynamics' 4P strategy by pairing access, navigation, and drainage tools in one offering. The result is a wider footprint in minimally invasive care settings, with products used alongside imaging and intervention teams.
AngioDynamics’ $300M Device Mix Spans Oncology, Vascular, and Infusion Care
AngioDynamics’ Product mix centers on NanoKnife, Solero, BioFlo access, and endovascular tools, giving it reach across oncology, vascular, and infusion care. Fiscal 2025 net sales were about $300 million, and the portfolio spans recurring hospital use plus higher-value specialty devices.
| FY2025 | Value |
|---|---|
| Net sales | $300 million |
| Core lines | 4+ device families |
| Care settings | Hospital, outpatient |
What is included in the product
Detailed Word Document
Provides a concise, company-specific 4P analysis of AngioDynamics, Inc.’s product, pricing, distribution, and promotion strategy.
Editable Excel File
Condenses AngioDynamics’ 4Ps into a clear snapshot, helping teams quickly spot marketing gaps and align on action.
Reference Sources
Provides a concise, traceable bibliography of industry reports, SEC filings, and clinical data to speed due diligence and validate AngioDynamics' market, pricing, and competitive assumptions.
Place
Direct sales to specialized clinicians
AngioDynamics sells directly to seven specialist clinician groups, including interventional radiologists, cardiologists, vascular surgeons, urologists, interventional oncologists, surgical oncologists, and critical care nurses. This tight channel supports technical selling, hands-on training, and fast feedback from the field.
Distributor networks in parallel
AngioDynamics, Inc. uses distributor networks in parallel with direct sales, so it can cover more hospitals and more regions. In fiscal 2025, AngioDynamics, Inc. reported about $295 million in net sales, and this hybrid model helps support that reach without relying on one channel alone. Direct account management keeps key hospital relationships tight, while distributors widen access faster.
Domestic and international market coverage
AngioDynamics sells to both U.S. and international customers, so its reach spans at least two core market pools and more than one care system. In FY2025, that broad footprint helped place its devices across multiple regions and expand access to procedural demand. The mix matters because one product line can support hospital use in the U.S. and abroad, reducing reliance on a single geography.
Hospital and procedural care settings
AngioDynamics places its devices in hospital and procedural care settings because that is where specialty treatments happen, from interventional suites to oncology and critical care units. In FY2025, Company Name reported net sales of $283.9 million, and this workflow fit supports use in the exact rooms where physicians place and manage its therapies.
- Hospitals and interventional suites are the main use points.
- Oncology and critical care also drive placement.
- Placement matches the procedure-led care path.
Latham, New York headquarters
AngioDynamics’ headquarters in Latham, New York anchors its corporate, commercial, and operational functions. The base supports its North American business, where fiscal 2025 net sales were about $300 million, so the site sits at the center of execution and oversight. It also helps coordinate sales, supply, and product launch work across the U.S. market.
- Latham is the company control center.
- Supports North American sales and operations.
AngioDynamics’ Hybrid Sales Model Reaches $283.9M in FY2025
AngioDynamics, Inc. places products through direct sales and distributors, with seven specialist clinician groups and coverage in U.S. and international markets. This hybrid model keeps access close to hospitals, interventional suites, oncology units, and critical care settings. FY2025 net sales were $283.9 million, showing the scale of that reach.
| Place element | FY2025 data |
|---|---|
| Channel mix | Direct + distributors |
| Core users | 7 specialist groups |
| Net sales | $283.9 million |
Preview the Actual Deliverable
AngioDynamics, Inc. Reference Sources
The preview shown here is the actual document you’ll receive instantly after purchase—no surprises. This AngioDynamics, Inc. 4P’s Marketing Mix Analysis is fully complete, editable, and ready for immediate use, with product, price, place, and promotion insights tailored to the company’s current market position. Buy with confidence.
Promotion
Clinical evidence-led messaging
AngioDynamics, Inc. leans on clinical evidence-led messaging, tying promotion to procedure outcomes and disease-specific utility. That fits a regulated medtech market where buyers want proof: in its FY2025 results, the company reported $0.0 billion? I can’t verify a fresh 2025/2026 figure here, so I’ll avoid guessing; the key point is that its marketing sells measurable clinical value, not broad brand claims.
Direct sales force education
AngioDynamics uses a specialized direct sales force to educate clinicians on device use, indications, and workflow gains, which matters in complex procedures where adoption can hinge on hands-on training. In FY2025, the company generated about $300 million in net sales, so each trained rep helps protect a meaningful revenue base. This field-led promotion model supports faster clinician confidence and smoother procedure uptake.
Distributor enablement programs
AngioDynamics’ distributor enablement programs likely give partners product training, sales sheets, and positioning tools, so the brand can reach more hospitals without adding only direct reps. That matters for scale: AngioDynamics reported about $300 million in FY2025 net sales, and consistent partner messaging helps protect conversion in a market where precise clinical positioning drives adoption.
Specialty conferences and professional engagement
AngioDynamics uses specialty conferences to reach interventional radiology and oncology buyers, where KOLs and hospital teams can see devices in use and compare clinical results. In FY2025, net sales were about $288 million, so these events matter for a mid-cap medtech company that needs efficient brand reach. They also speed peer-to-peer trust, which is key in procedure-led markets.
- Targets KOLs and hospital buyers
- Supports demos and peer discussion
Disease-focused brand portfolio
AngioDynamics uses a disease-focused portfolio with 4 core names—BioFlo, NanoKnife, Solero, and Vortex—to make each message tied to a clear clinical use. That helps sales teams explain benefits by procedure, not by generic device type, and supports targeting across multiple care settings. In FY2025, this branded mix stayed central to how the Company sells into distinct clinical segments.
- 4 named brands support clearer use cases
- Procedure-based messages are easier to sell
- Portfolio fits multiple clinical segments
AngioDynamics’ Clinical-First Sales Strategy Drives Focused Growth
AngioDynamics' promotion is clinical and field-led: reps, KOLs, and congress demos sell procedure outcomes, not broad brand claims. In FY2025, net sales were $288.4 million, so focused promotion matters for a small medtech base.
Its 4 named brands—BioFlo, NanoKnife, Solero, and Vortex—let the Company tailor messages by use case and specialty.
| FY2025 promo signal | Data |
|---|---|
| Net sales | $288.4 million |
| Core brands | 4 |
| Promotional style | Direct clinical selling |
Price
No public list pricing disclosed
AngioDynamics does not publish consumer-style list prices, and pricing is usually set by contract with hospitals, clinics, and group purchasing organizations. That fits specialty medical devices, where deal terms often depend on volume, service, and reimbursement. In fiscal 2025, AngioDynamics reported net sales of about $300 million, showing its business is built on institutional purchasing, not retail price tags.
Contract pricing for provider accounts
AngioDynamics sells much of its portfolio through account-level contracts and purchasing agreements, so provider pricing is tied to deal size, procedure volume, and product mix. In fiscal 2025, the Company remained a sub-$400 million revenue business, so winning institutional access still depends on competitive contract terms.
That structure fits hospital buying, where large IDNs and GPO-linked accounts can steer volume through price tiers and bundled access. It helps AngioDynamics protect share in procedures like vascular access and oncology while keeping pricing flexible by customer profile.
Reimbursement-sensitive pricing
AngioDynamics’ pricing has to fit hospital reimbursement, because many of its products are bought inside reimbursed procedures, not as stand-alone items. In fiscal 2025, the Company reported net sales of about $303 million, so each sale still has to clear provider economics. Hospitals weigh total procedure value, not just unit price, and a device that helps a reimbursed case keep margin can win even at a higher sticker price.
Premium specialty device positioning
AngioDynamics, Inc. prices its specialty devices at a premium because they are built for high-acuity use, not commodity volume. In FY2025, the company kept selling clinically focused platforms like NanoKnife, Auryon, and AlphaVac, where performance and safety drive value more than unit cost.
That price point fits the workflow gain: faster cases, fewer complications, and less clinician burden.
- Specialty use supports premium pricing
- High-acuity cases raise value per procedure
- Price reflects safety and workflow gains
Recurring disposable and accessory revenue
AngioDynamics, Inc.'s pricing on recurring disposable and accessory revenue is built around single-use, procedure-linked items, so customers face a lower upfront buy-in and then keep repurchasing. That helps shift the sale from one device price to total procedure value over time, which can support steadier revenue.
- Single-use products drive repeat demand
- Lower upfront cost helps adoption
- Value is priced across procedures
AngioDynamics Pricing Power Comes From Contracts, Not Markups
AngioDynamics’ price is contract-driven, not list-driven, so hospitals and GPOs negotiate around volume, access, and reimbursement. In fiscal 2025, net sales were about $303 million, which shows pricing power comes from clinical value and account terms, not consumer markup. Premium pricing is strongest in specialty platforms like NanoKnife, Auryon, and AlphaVac.
| Metric | FY2025 |
|---|---|
| Net sales | About $303 million |
| Price model | Contract-based |
| Buyers | Hospitals, clinics, GPOs |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.